Grifols S A SEC Filings

GRFS NASDAQ

Welcome to our dedicated page for Grifols S A SEC filings (Ticker: GRFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Locating donor-center counts, FDA inspection updates, or immunoglobulin margin trends in a 300-page bioscience filing can feel overwhelming. Grifols’ disclosures are packed with plasma-collection metrics, hospital-product data, and complex clinical trial notes—exactly the information analysts need yet struggle to extract.

Stock Titan solves this problem. Our AI reads every Grifols annual report 10-K simplified, Grifols quarterly earnings report 10-Q filing, and Grifols 8-K material events explained the moment they hit EDGAR. It translates bioscience jargon into clear takeaways: how new immunoglobulin batches affect revenue, which diagnostic tests gained regulatory clearance, and where R&D spending is headed. Real-time alerts flag Grifols Form 4 insider transactions real-time, letting you track Grifols executive stock transactions Form 4 before the market digests them.

Want to know why donor-compensation costs moved last quarter? Need the latest segment sales breakout without combing through footnotes? Our platform offers:

AI-powered summaries for every filing—Grifols SEC filings explained simply
Instant search across 10-K, 10-Q, 8-K, 13D/G, and Grifols proxy statement executive compensation
Custom dashboards for Grifols earnings report filing analysis and plasma-center KPIs
Automatic alerts for Grifols insider trading Form 4 transactions

Save hours decoding regulatory language and focus on decisions, not document hunting. With Stock Titan, understanding Grifols SEC documents with AI becomes straightforward—so you can act on insights while others are still scrolling.

07/30/2025 06:12 AM

Filing

[6-K] Grifois, S.A. Current Report (Foreign Issuer)

Rhea-AI Summary

Grifols’ H1-25 results show solid operating momentum and meaningful deleveraging. Revenue rose 7.0% cc to EUR 3.68 bn, fueled by Biopharma +8.2% cc with IG volumes up 12.5% and SCIG +66%. Adjusted EBITDA climbed 12.7% cc to EUR 876 m, lifting margin 80 bps to 23.8% despite IRA headwinds. Net profit jumped nearly 4-fold to EUR 177 m, aided by lower restructuring costs and improved finance charges.

Free cash flow pre-M&A improved EUR 182 m YoY to -14 m (EUR 30 m positive in Q2); leverage fell to 4.2× (5.5× a year earlier) with liquidity of EUR 1.4 bn. The company reinstated a EUR 0.15/share dividend, finalized Biotest delisting to reach 80.3% ownership (EUR 108 m outlay), and reiterated FY-25 guidance while raising FCF pre-M&A outlook to EUR 375-425 m. Pipeline execution remains on track, targeting EU launch of fibrinogen in Q4-25 and US launch H1-26.

Management warns that a weaker USD will pressure reported H2 revenue & EBITDA, but expects neutral impact on profit, leverage and FCF through cost levers. Segment detail: Diagnostic +2.8% cc, BioSupplies -31.8% cc. Albumin declined 3.7% cc YTD but returned to growth in Q2. Overall, the Value Creation Plan is delivering margin gains, cash-flow recovery and balance-sheet repair, though free cash flow and net debt (EUR 9.1 bn) remain key watch points.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

[6-K] Grifois, S.A. Current Report (Foreign Issuer)

Rhea-AI Summary

Grifols (GRFS) has declared an interim cash dividend of €0.15 per share against FY-2025 earnings. The Board approved the payment on 28 Jul 2025, representing a total cash outlay of €102.1 m after excluding 7.0 m treasury shares. Key timetable:

Last trading date: 8 Aug 2025
Ex-dividend: 11 Aug 2025
Record date: 12 Aug 2025
Payment date: 13 Aug 2025

Gross amount per share is €0.15; after the standard 19 % Spanish withholding tax, shareholders will receive €0.1215 net unless reduced by treaty or exemption. The distribution covers 687.6 m outstanding shares (426.1 m Class A at €0.25 par; 261.4 m Class B at €0.05 par). BBVA acts as paying agent and Iberclear will execute settlement. No additional financial or operating results were disclosed in this Form 6-K.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

[6-K] Grifois, S.A. Current Report (Foreign Issuer)

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Grifols S A (GRFS)?

The current stock price of Grifols S A (GRFS) is $10.7 as of July 31, 2025.

What is the market cap of Grifols S A (GRFS)?

The market cap of Grifols S A (GRFS) is approximately 7.1B.

What is the core business of Grifols S A?

Grifols S A is primarily engaged in the collection of plasma and the development, production, and distribution of plasma-derived therapies, in addition to offering innovative diagnostic and hospital-related pharmaceutical products.

How is Grifols organized in terms of business divisions?

The company operates through three main divisions: Bioscience, which covers plasma collection and therapy production; Diagnostic, which develops clinical tests and transfusion solutions; and Hospital, which provides non-biological pharmaceutical products.

In which sectors does Grifols have a significant market presence?

Grifols holds a strong position in the plasma-derived medicines sector and is critical in transfusion medicine, immunoglobulin production, and diagnostic solutions, with a presence in more than 100 countries globally.

What distinguishes Grifols S A from its competitors?

Its vertically integrated model allows Grifols to control the entire process from plasma collection through manufacturing to distribution, which enhances quality control, innovation and operational efficiency.

Does Grifols invest in research and innovation?

Yes, the company consistently invests in research and development to advance its plasma-derived products, improve treatment protocols and introduce innovative diagnostic and biosurgical solutions.

What types of products does Grifols manufacture?

Grifols produces a diverse array of healthcare products, including plasma-derived immunoglobulins, fibrin sealants used in surgery, and advanced diagnostic tests for detecting infectious and autoimmune diseases.

How does Grifols ensure product quality and safety?

The company adheres to strict regulatory standards, implementing advanced quality control measures and robust clinical protocols at every stage of its production—from plasma collection through to the final product distribution.

What is Grifols S A's global impact in healthcare?

Grifols significantly contributes to global healthcare by providing life-saving plasma-derived therapies and diagnostic solutions that support efficient and safe patient care across diverse medical fields.